Gorczynska Ewa, Turkiewicz Dominik, Rybka Katarzyna, Toporski Jacek, Kalwak Krzysztof, Dyla Agnieszka, Szczyra Zofia, Chybicka Alicja
Department of Pediatric Hematology, Oncology and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, Poland.
Biol Blood Marrow Transplant. 2005 Oct;11(10):797-804. doi: 10.1016/j.bbmt.2005.06.007.
We analyzed the incidence, etiology, risk factors, and clinical management of hemorrhagic cystitis (HC) in 102 children who underwent allogeneic stem cell transplantation: 28 from matched siblings, 57 from unrelated donors, and 17 from mismatched relatives. Conditioning regimens consisted of high-dose chemotherapy (n=83) or total body irradiation (n=19). In all children, urine and plasma were prospectively screened for human polyomavirus (HPV; BK virus [BKV] and JC virus [JCV]) or adenovirus (AdV) DNA with a polymerase chain reaction-based assay. Viral DNA was detected in the urine of 56 children (54.9%): BKV in 48 (47%), JCV in 4 (3.9%), and AdV in 4 (3.9%). HC occurred in 26 children (25.5%), and viruria was detected in all of them: BKV in 21 (80.8%), AdV in 4 (14.4%), and JCV in 1 (3.8%). All patients with AdV viruria developed HC. The cumulative incidence of HC in patients with HPV viruria was 0.43. The only significant risk factor for HC in patients with HPV-positive urine was conditioning with high-dose chemotherapy. Twenty-two children were treated with cidofovir, with no significant toxicity. In all treated patients but 1, the clinical symptoms were moderate, and no HC-related death was observed. We conclude that virus-induced HC is a frequent complication after allogeneic hematopoietic cell transplantation. Treatment with cidofovir is feasible, and further studies are warranted to evaluate its activity in HC mediated by BKV or JCV.
我们分析了102例接受异基因干细胞移植儿童的出血性膀胱炎(HC)的发病率、病因、危险因素及临床处理情况:其中28例来自匹配的同胞,57例来自无关供者,17例来自不匹配的亲属。预处理方案包括大剂量化疗(n = 83)或全身照射(n = 19)。对所有儿童的尿液和血浆均采用基于聚合酶链反应的检测方法前瞻性筛查人多瘤病毒(HPV;BK病毒[BKV]和JC病毒[JCV])或腺病毒(AdV)DNA。在56例儿童(54.9%)的尿液中检测到病毒DNA:BKV 48例(47%),JCV 4例(3.9%),AdV 4例(3.9%)。26例儿童(25.5%)发生了HC,且所有这些患儿均检测到病毒尿:BKV 21例(80.8%),AdV 4例(14.4%),JCV 1例(3.8%)。所有AdV病毒尿患儿均发生了HC。HPV病毒尿患儿中HC的累积发病率为0.43。HPV阳性尿液患儿发生HC的唯一显著危险因素是接受大剂量化疗预处理。22例儿童接受了西多福韦治疗,无明显毒性。除1例患儿外,所有接受治疗的患儿临床症状均为中度,未观察到与HC相关的死亡。我们得出结论,病毒诱导的HC是异基因造血细胞移植后常见的并发症。西多福韦治疗是可行的,有必要进一步研究以评估其在BKV或JCV介导的HC中的活性。